<DOC>
	<DOCNO>NCT02097264</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate mechanism action NNC0109-0012 ( anti-IL-20 mAb ) synovial biopsy subject rheumatoid arthritis ( RA ) inadequate response Methotrexate .</brief_summary>
	<brief_title>A Trial Investigating Mechanism Action NNC0109-0012 ( Anti-IL-20 mAb ) Through Synovial Biopsies Subjects With Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female age least 18 equal 75 year time signing inform consent A diagnosis RA least 6 month prior screen visit , accord American College Rheumatology ( EULAR/ACR 2010 criterion ) standard criterion ( ACR 1987 ) diagnosis make earlier 2010 Subjects ACR global functional status 1 3 Active RA , characterise : DAS28 ( Disease Activity Score 28 ) ( CRP ( Creactive protein ) ) 4.5 equal 6 tender equal 6 swollen joint base 66/68 joint count Active Synovitis least two joint wrist metacarpophalangeal joint , assess high frequency Power Doppler ultrasound scan screen randomisation Subjects arthritis due autoimmune disease RA Body weight 90.0 kg History current inflammatory joint disease RA ( e.g . gout , psoriatic reactive arthritis , Lyme disease , juvenile idiopathic arthritis , exclude secondary Sjogren syndrome hypothyroidism ) Any active ongoing bacterial infection within 4 week prior screen visit , unless treat resolved appropriate therapy history recurrent infection condition predispose chronic infection ( e.g. , bronchiectasis , chronic osteomyelitis ) Subjects malignancy within previous 5 year exception adequately treat cured basal squamous cell carcinoma skin cervical carcinoma situ occur 12 month prior screen visit Female pregnant , breast feeding , intend become pregnant childbearing potential , willing use two highly effective contraceptive method ( adequate highlyeffective contraceptive measure define establish use oral , injected implant hormonal method contraception , sterilisation , intrauterine device intrauterine system ) one barrier method barrier method contraception ( e.g . condom spermicidal foam/gel/film/cream ) , least 16 week ( approximately 5 halflives ) follow last dose trial medication Male subject sexually active surgically sterilise , whose partner unwilling use two different form highly effective contraception , one barrier method barrier method contraception ( e.g . condom spermicidal foam/gel/film/cream ) duration trial least 16 week ( approximately 5 halflives ) follow last dose trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>